SGLT-2 Therapy Center

Could empagliflozin contribute to the early treatment of NAFLD in patients with T2DM? 

SGLT2 Inhibitors and their use for preventing cardiovascular diseases. 

SGLT-2 inhibitors have proved to be successful hypoglycemics, so should they be recommended earlier for those not achieving goal A1c reductions? 

A female patient, 42 years of age, with type 2 diabetes, is overweight with a history of vaginal yeast infections with elevated glucose levels. Wanting to better manage her diabetes and lose some weight, the commercials about SGLT-2 inhibitors caught her attention.

More may be better unless it involves tablets. A newly approved, more straightforward way to treat type 2 diabetes.

The use of SGLT2 inhibitors was associated with reduced risk of any cause of death in patients with or without a history of major cardiovascular disease.

Examining both the clinical and the cost outcomes for patients with type 2 diabetes with established cardiovascular disease.

Could a newer diabetes medication provided clinicians with an alternative when managing heart failure?

The persistence of benefits of dapagliflozin over saxagliptin might change therapy choices in patients with type 2 diabetes.

While rare, Fournier gangrene infections can worsen rapidly and have serious consequences.